The role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) in modern rheumatology

Therapeutic Advances in Musculoskeletal Disease

Volumn 2, Issue 5, 2010, Pages 257-269

  Kotyla, Przemyslaw ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

connective tissue diseases; pleiotropic effect; rheumatology; statins

Indexed keywords

EID: 84993740371     PISSN: 1759720X     EISSN: None     Source Type: Journal    
DOI: 10.1177/1759720X10384307     Document Type: Review

References (103)

1. Abud-Mendoza, C., de la Fuente, H., Cuevas-Orta, E., Baranda, L., Cruz-Rizo, J. and Gonzalez-Amaro, R. ( 2003) Therapy with statins in patients with refractory rheumatic diseases: A preliminary study. Lupus 12: 607-611.
2. Aktas, O., Waiczies, S., Smorodchenko, A., Dorr, J., Seeger, B., Prozorovski, T. et al. (2003) Treatment of relapsing paralysis in experimental encephalomyelitis by targeting Th 1 cells through atorvastatin. J Exp Med 197: 725-733.
3. Aoki, I., Aoki, N., Kawano, K., Shimoyama, K., Maki, A., Homori, M. et al. (1997) Platelet-dependent thrombin generation in patients with hyperlipidemia. J Am Coll Cardiol 30: 91-96.
4. Baecher-Allan, C., Brown, J.A., Freeman, G.J. and Hafler, D.A. ( 2001) CD4+CD25 high regulatory cells in human peripheral blood. J Immunol 167: 1245-1253.
5. Barandier, C., Ming, X.F. and Yang, Z. ( 2003) Small G proteins as novel therapeutic targets in cardiovascular medicine. News Physiol Sci 18: 18-22.
6. Botazzo, G.F., Pujol-Borrel, R., Hanafusa, T. and Feldmann, M. ( 1983) Role of aberrant HLA-DR expression and antigen presentation in induction of endocrine autoimmunity. Lancet 2: 1115-1119.
7. Braga, V.M.M. ( 2002) Cell-cell adhesion and signaling. Curr Opin Cell Biol 14: 546-556.
8. Bulkley, B.H. and Roberts, W.C. ( 1975) The heart in systemic lupus erythematosus and the changes induced in it by the corticosteroid therapy. A study of 36 necropsy patients. Am J Med 58: 243-264.
9. Camera, M., Toschi, V., Comparato, C., Baetta, R., Rossi, F., Fuortes, M. et al. (2002) Cholesterol-induced thrombogenicity of the vessel wall: Inhibitory effect of fluvastatin. Thromb Haemost 87: 748-755.
10. Cipollone, F., Fazia, M., Iezzi, A., Zucchelli, M., Pini, B., de Cesare, D. et al. (2003) Suppression of the functionally coupled cyclooxygenase-2/prostaglandin E synthase as a basis of simvastatin dependent plaque stabilization in humans. Circulation 107: 1479-1485.
11. Clark, D.A. and Coker, R. ( 1998) Transforming growth facto-beta (TGF-β). Int J Biochem Cell Biol 30: 293-298.
12. Cohen, L.H., Pieterman, E., van Leeuwen, R.E., Overhand, M., Burm, B.E., van der Marel, G.A. et al. (2000) Inhibitors of prenylation of Ras and other G-proteins and their application as therapeutics. Biochem Pharmacol 60: 1061-1068.
13. Colicelli, J. ( 2004) Human RAS superfamily proteins and related GTPases. Sci STKE 250: RE13.
14. Colli, S., Eligini, S., Lalli, M., Camera, M., Paoletti, R. and Tremoli, E. ( 1997) Vastatins inhibit tissue factor in cultured human macrophages: A novel mechanism of protection against atherothrombosis. Arterioscler Thromb Vasc Biol 17: 265-272.
15. Comparato, C., Altana, C., Bellosta, S., Baetta, R., Paoletti, R. and Corsini, A. ( 2001) Clinically relevant pleiotropic effects of statins: Drug properties or effects of profound cholesterol reduction? Nutr Metab Cardiovasc Dis 11: 328-343.
16. Corsini, A., Mazzotti, M., Raiteri, M., Soma, M.R., Gabbiani, G., Fumagalli, R. et al. (1993) Relationship between mevalonate pathway and arterial myocyte proliferation: In vitro studies with inhibitors of HMGCoA reductase. Atherosclerosis 1001: 117-125.
17. Corsini, A., Pazzucconi, F., Arnaboldi, L., Pfister, P., Fumagalli, R., Paoletti, R. et al. (1998) Direct effects of statins on the vascular wall. J Cardiovasc Pharmacol 31: 773-778.
18. Costenbader, K.H., Liang, M.H., Chibnik, L.B., Aizer, J., Kwon, H., Gall, V. et al. (2007) A pravastatin dose-escalation study in systemic lupus erythematosus. Rheumatol Int 27: 1071-1077.
19. Cristea, A., Rus, H., Niculescu, F., Bedeleanu, D. and Vlaicu, R. ( 1986) Characterization of circulating immune complexes in heart disease. Immunol Lett 13: 45-49.
20. Dahlback, B. ( 2000) Blood coagulation. Lancet 355: 1627-1632.
21. Daniel, J.L., Dangelmaier, C., Jin, J., Kim, Y.B. and Kunapuli, S.P. ( 1999) Role of intracellular signaling events in ADP-induced platelet aggregation. Thromb Haemost 82: 1322-1326.
22. de Kruif, M.D., Limper, M., Hansen, H.R., de Ruiter, J., Spek, C.A. and van Gorp, E.C. (2009) Effects of a 3-month course of rosuvastatin in patients with systemic lupus erythematosus. Ann Rheum Dis 68: 1654.
23. Esdaile, J.M., Abrahamowicz, M., Grodzicky, T., Li, Y., Panaritis, C., du Berger, R. et al. (2001) Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 44: 2331-2337.
24. Esteve, E., Castro, A., Lopez-Bermejo, A., Endrell, J., Ricart, W. and Fernandez-Real, J.M. ( 2007) Serum interleukin-6 correlates with endothelial dysfunction in healthy men independently of insulin sensitivity. Diabetes Care 30: 939-945.
25. Etienne-Manneville, S. and Hall, A. ( 2002) Rho GTPases in cell biology. Nature 420: 629-635.
26. Eto, M., Barandiér, C., Rathgeb, L., Kozai, T., Joch, H., Yang, Z. et al. (2001) Thrombin suppresses endothelial nitric oxide synthase and upregulates endothelin converting enzyme-1 expression by distinct pathways: Role of Rho/ROCK and mitogen-activated protein kinase. Circ Res 89: 583-590.
27. Eto, M., Kozai, T., Cosentino, F., Joch, H. and Lüscher, T.F. ( 2002) Statins prevent tissue factor expression in human endothelial cells: Role of Rho/Rho-kinase and Akt pathways. Circulation 87: 748-755.
28. Ferreira, G.A., Navarro, T.P., Telles, R.W., Andrade, L.E. and Sato, E.I. ( 2007) Atorvastatin therapy improves endothelial-dependent vasodilation in patients with systemic lupus erythematosus: An 8 week controlled trial. Rheumatology (Oxford) 46: 1560-1565.
29. Ferro, D., Basili, S., Alessandri, C., Cara, D. and Violi, F. ( 2000) Inhibition of tissue-factor-mediated thrombin generation by simvastatin. Atherosclerosis 149: 111-116.
30. Frazie, K., Williams, S., Kothapalli, D., Klapser, H. and Grotendorst, G.R. ( 1996) Stimulation of fibroblast cell growth, matrix production, and granulation tissue formation by connective tissue growth factor. J Invest Dermatol 107: 404-411.
31. Fuster, V., Badimon, L., Badimon, J.J. and Chesebro, J.H. ( 1992) The pathogenesis of coronary artery disease and acute coronary syndromes 2. N Engl J Med 326: 310-318.
32. George, J., Afek, A., Keren, P., Herz, I., Goldberg, I., Haklai, R. et al. (2002) Functional inhibition of Ras by s-trans, trans-farnesyl thiosalicylic acid attenuates atherosclerosis in apolipoprotein E knockout mice. Circulation 105: 2416-2422.
33. Glomset, J.A. and Farnsworth, C.C. ( 1994) Role of protein modification reactions in programming interactions between ras-related GTPases and cell membranes. Annu Rev Cell Biol 10: 181-205.
34. Hakamada-Taguchi, R., Uehara, Y., Kuribayashi, K., Numabe, A., Saito, K., Negoro, H. et al. (2003) Inhibition of hydroxymethylglutaryl coenzyme A reductase reduces Th 1 development and promotes Th 2 development. Circ Res 93: 948-956.
35. Han, K.H., Ryu, J., Hong, K.H., Ko, J., Pak, Y.K., Kim, J.B. et al. (2005) HMG-CoA reductase inhibition reduces monocyte CC chemokine receptor 2 expression and monocyte chemoattractant protein-1 mediated monocyte recruitment in vivo. Circulation 111: 1439-1447.
36. Hanson, J. and Bossingham, D. ( 1998) Lupus-like syndrome associated with simvastatin. Lancet 352: 1070.
37. Heinrich, J. and Assmann, G. ( 1995) Fibrinogen and cardiovascular risk. J Cardiovasc Risk 2: 197-205.
38. Henney, A.M., Wakeley, P.R., Davies, M.J., Foster, K., Hembry, R., Murphy, G. et al. (1991) Localization of stromelysin gene expression in atherosclerotic plaques by in situ hybridization. Proc Natl Acad Sci U S A 88: 8154-8158.
39. Johnsson, H., Nived, O. and Sturfelt, G. ( 1989) Outcome in systemic lupus erythematosus: A prospective study of patients from a defined population. Medicine ( Baltimore) 68: 141-150.
40. Kanda, H., Hamasaki, K., Kubo, K., Tateishi, S., Yonezumi, A., Kanda, Y. et al. (2002) Antiniflammatory effect of simvastatin in
41. patients with rheumatoid arthritis. J Rheumatol 29: 2024-2026.
42. Kaneider, N.C., Egger, P., Dunzendorfer, S. and Wiedermann, C.J. ( 2002) Rho-GTPase-dependent platelet-neutrophil interaction affected by HMG-CoA reductase inhibition with altered adenosine nucleotide release and function. Arterioscler Thromb Vasc Biol 22: 1029-1035.
43. Kim, Y.C., Kim, K.K. and Shevach, E.M. (2010) Simvastatin induces Foxp 3 T regulatory cells by modulation of transforming growth factor-beta signal transduction. Immunology 130: 484-493.
44. Kotyla, P.J. (2009) Pravastatin, a 3-hydroxy-3-methylglutharyl coenzyme A inhibitor does not show pleiotropic effects in patients with systemic lupus erythematosus. Rheumatol Int 29: 353-354.
45. Kotyla, P.J., Sliwinska-Kotyla, B. and Kucharz, E.J. ( 2006) TNF alpha as a potential target in the treatment of SLE: A Role for the HMG-CoA reductase inhibitor simvastatin. J Rheumatol 33: 2361.
46. Krysiak, R., Okopień, B. and Herman, Z.S. ( 2003) Effects of HMG-CoA reductase inhibitors on coagulation and fibrinolysis processes. Drugs 63: 1821-1854.
47. Kwak, B., Mulhaupt, F., Myit, S. and Mach, F. ( 2000) Statins as newly recognized type of immunomodulator. Nat Med 6: 1399-1402.
48. Kwak, B., Mulhaupt, F., Veillard, N., Pelli, G. and Mach, F. ( 2001) The HMG-CoA reductase inhibitor simvastatin inhibits IFN-gamma induced MHC class II expression in human vascular endothelial cells. Swiss Med Wkly 131: 41-46.
49. Lawman, S., Mauri, C., Jury, E.C., Cook, H.T. and Ehrenstein, M.R. ( 2004) Atorvastatin inhibits auto-reactive B cell activation and delays lupus development in New Zeland Black/White F 1 mice. J Immunol 173: 7641-7646.
50. Leung, B.P., Sattar, N., Crilly, A., Prach, M., McCarey, D.W., Payne, H. et al. (2003) A novel antiinflammatory role for simvastatin in inflammatory arthritis. J Immunol 170: 1524-1530.
51. Li, C., Lim, S.W., Choi, B.S., Lee, S.H., Cha, J.H., Kim, I.S. et al. (2005) Inhibitory effect of pravastatin on transforming growth factor β1-inducible gene h 3 expression in a rat model of chronic cyclosporine nephropathy. Am J Nephrol 25: 611-620.
52. Liao, J.K. ( 2002) Isoprenoids as mediators of the biological effect of statins. J Clin Invest 110: 285-288.
53. Libby, P., Ridker, P.M. and Maseri, A. ( 2002) Inflammation and atherosclerosis. Circulation 105: 1135-1143.
54. Lin, H., Xiao, Y., Chen, G., Fu, D., Ye, Y., Liang, L. et al. (2010) HMG-CoA reductase inhibitor simvastatin suppresses Toll-like receptor 2 ligand-induced activation of nuclear factor kappa B by preventing RhoA activation in monocytes from rheumatoid arthritis patients. Rheumatol Int, [Epub ahead of print].
55. Liu, M.F., Wang, C.R., Fung, L.L. and Wu, C.R. ( 2004) Decreased CD4+CD25+ T cells in peripheral blood of patients with systemic lupus erythematosus. Scand J Immunol 59: 198-202.
56. Liuzzo, G., Kopecky, S.L., Frye, R.L., O'Fallon, W.M., Maseri, A., Goronzy, J.J. et al. (1999) Perturbation of the T-cell repertoire in patients with unstable angina. Circulation 100: 2135-2139.
57. Louneva, N., Huaman, G., Fertala, J. and Jimenez, S.A. ( 2006) Inhibition of systemic sclerosis dermal fibroblast type I collagen production and gene expression by simvastatin. Arthritis Rheum 54: 1298-1308.
58. Mackay, D.J. and Hall, A. ( 1998) Rho GTPases. J Biol Chem 273: 20685-20688.
59. Mahmud, A. and Feely, J. ( 2005) Arterial stiffness is related to systemic inflammation in essential hypertension. Hypertension 46: 1118-1122.
60. Manzi, S., Meilahn, E.N., Rairie, J.E., Conte, C.G., Medsger Jr, T.A., Jansen-McWilliams, L. et al. (1997) Age specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: Comparison with the Framingham Study. Am J Epidemiol 145: 408-415.
61. Maradit-Kremers, H., Crownson, C.S., Nicola, P.J., Ballman, K.V., Roger, V.L., Jacobsen, S.J. et al. (2005) Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: A population-based cohort study. Arthritis Rheum 52: 402-411.
62. McCarey, D.W., McInnes, I.B., Madhok, R., Hampson, R., Scherbakov, O., Ford, I. et al. (2004) Trial of atorvastatin in rheumatoid arthritis (TARA): Double blind, randomized placebo controlled trial. Lancet 363: 2015-2021.
63. Meroni, P.L. and Tremoli, E. ( 2003) Modulation of adhesion molecule expression on endothelial cells: To be or not to be? J Thromb Haemost 1: 2280-2282.
64. Mezzetti, A. ( 2005) Pharmacological modulation of plaque instability. Lupus 14: 769-772.
65. Musiał, J., Undas, A., Undas, R., Brozek, J. and Szczeklik, A. ( 2001) Treatment with simvastatin and low-dose aspirin depresses thrombin generation in patients with coronary heart disease and borderline-high cholesterol levels. Thromb Haemost 85: 221-225.
66. Mustafa, A., Nityanand, S., Berglund, L., Lithell, H. and Lefvert, A.K. ( 2000) Circulating immune complexes in 50-year-old men as a strong and independent risk factor for myocardial infarction. Circulation 102: 2576-2581.
67. Navab, M., Berliner, J.A., Watson, A.D., Hama, S.Y., Territo, M.C., Lusis, A.J. et al. (1996) The yin and yang of oxidation in the development of fatty streak: A review based on 1994 George Lymann Duff Memorial Lecture. Arterioscler Thromb Vasc Biol 16: 831-842.
68. Petri, M. ( 2000) Detection of coronary artery disease and the role of traditional risk factors in the Hopkins lupus cohort. Lupus 9: 170-175.
69. Pierre-Paul, D. and Gahtan, V. ( 2003) Noncholesterollowering effects of statins. Vasc Endovascular Surg 37: 301-313.
70. Porreca, E., Di, F.C., Baccante, G., Di, N.M. and Cuccurullo, F. ( 2002) Increased transforming growth factor-beta (1) circulating levels and production in human monocytes after 3-hydroxy-3-methyl-glutarylcoenzyme a reductase inhibition with pravastatin. J Am Coll Cardiol 39: 1752-1757.
71. Postlethwaite, A.E. ( 1995) Role of T cells and cytokines in effecting fibrosis. Int Rev Immunol 12: 247-258.
72. Riessen, R., Axel, D.I., Fenchel, M., Herzog, U.U., Rossmann, H. and Karsch, K.R. ( 1999) Effect of HMG-CoA reductase inhibitors on extracellular matrix expression in human vascular smooth cells. Basic Res Cardiol 94: 322-332.
73. Roman, M.J., Salmon, J.E., Sobel, R., Lockshin, M.D., Sammaritano, L., Schwartz, J.E. et al. (2001) Prevalance and relation to risk factors of carotid atherosclerosis and left ventricular hypertrophy in systemic lupus erythematosus and antiphospholipid antibody syndrome. Am J Cardiol 87: 663-666.
74. Romano, M., Diomede, L., Sironi, M., Massimiliano, L., Sottocorno, M., Polentarutti, N. et al. (2000 a) Inhibition of monocyte chemotactic protein-1 synthesis by statins. Lab Invest 80: 1095-1100.
75. Romano, M., Mezzetti, A., Marulli, C., Ciabattoni, G., Febo, F., Di Ienno, S. et al. (2000 b) Fluvastatin reduces soluble P-selectin and ICAM-1 levels in hypercholesterolemic patients: Role of nitric oxide. J Investig Med 48: 183-189.
76. Rosenbloom, J., Saitta, B., Gaidarova, S., Sandorfi, N., Rosenbloom, J.C., Abrams, W.R. et al. (2000) Inhibition of type I gene expression in normal and systemic sclerosis fibroblasts by a specific inhibitor of geranylgeranyl transferase I. Arthritis Rheum 43: 1624-1632.
77. Rosenson, R.S. and Tangney, C.C. ( 1998) Antiatherothrombotic properties of statins: Implications for cardiovascular event reduction. JAMA 279: 1643-1650.
78. Rosenson, R.S., Tangney, C.C. and Schaefer, E.J. ( 2001) Comparative study of HMG-CoA reductse inhibitors on fibrinogen. Atherosclerosis 155: 463-466.
79. Ross, R. ( 1999) Atherosclerosis an inflammatory disease. N Eng J Med 340: 115-126.
80. Ryan, S.T., Koteliansky, V.E., Gotwals, P.J. and Lindner, V. ( 2003) Transforming growth factor-beta-dependent events in vascular remodeling following arterial injury. J Vasc Res 40: 37-46.
81. Sadeghi, M.M., Tiglio, A., Sadigh, K., O'Donnell, L., Collinge, M., Pardi, R. et al. (2001) Inhibition of interferon-gamma-mediated microvascular endothelial cell major histocompatibility complex class II gene activation by HMG-CoA reductase inhibitors. Transplantation 71: 1262-1268.
82. Schror, K. ( 1995) Antiplatelet drugs. A comparative review. Drugs 50: 7-28.
83. Somlyo, A.P. and Somlyo, A.V. ( 2000) Signal transduction by G-proteins, Rho-kinase and protein phosphatase to smooth muscle and non-muscle myosin II. J Physiol 522: 177-185.
84. Song, J.C. and White, C.M. ( 2001) Do HMG-CoA reductase inhibitors affect fibrinogen. Ann Pharmacother 35: 236-241.
85. Szczeklik, A., Musiał, J., Undas, A., Gajewski, P., Gόra, P. and Swadźba, J. ( 1999) Inhibition of thrombin generation by simvastatin and lack of additive effects of aspirin in patients with marked hypercholesterolemia. J Am Coll Cardiol 33: 1286-1293.
86. Takai, Y., Sasaki, T. and Matozataki, T. ( 2001) Small GTP-binging proteins. Physiol Rev 81: 153-208.
87. Takemoto, M. and Liao, J.K. ( 2001) Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arterioscler Thromb Vasc Biol 11: 328-343.
88. Tan, A., Levrey, H., Dahm, C., Polunovsky, V.A., Rubins, J., Bitterman, P.B. et al. (1999) Lovastatin induces fibroblast apoptosis in vitro and in vivo: A possible therapy for fibroproliferative disorders. Am J Respir Crit Care Med 159: 220-227.
89. Urowitz, M.B., Bookman, A.A., Koehler, B.E., Gordon, D.A., Smythe, H.A. and Ogryzlo, M.A. ( 1976) The bimodal mortality pattern of systemic lupus erythematosus. Am J Med 60: 221-225.
90. Valencia, X., Yarboro, C., Illei, G. and Lipsky, P.E. ( 2007) Deficient CD4+CD25 high T regulatory cell function in patients with active systemic lupus erythematosus. J Immunol 178: 2579-2588.
91. van Haelst, P.L., van Doormaal, J.J., May, J.F., Gans, R.O., Crijns, H.J. and Cohen-Tervaert, J.W. ( 2001) Secondary prevention with fluvastatin decreases levels of adhesion molecules, neopterin and C reactive protein. Eur J Intern Med 12: 503-509.
92. Varga, J., Rosenbloom, J. and Jimenez, S.A. ( 1987) Transforming growth factor beta (TGF-beta) causes a persistent increase in steady-state amounts of type I and type III collagen and fibronectin mRNAs in normal human dermal fibroblasts. Biochem J 247: 597-604.
93. Vaughan, C.J. and Gotto, A.M. ( 2004) Update on statins: 2003. Circulation 110: 886-892.
94. Vaughan, C.J., Gotto, A.M. and Basson, C.T. ( 2000) The evolving role of statins in the management of atherosclerosis. J Am Coll Cardiol 35: 1-10.
95. Warkentin, T.E. ( 1995) Hemostasis and atherosclerosis. Can J Cardiol 11(Suppl C): 29-34.
96. Watts, G.M., Beurskens, F.J., Martin-Padura, I., Ballantyne, C.M., Klickstein, L.B., Brenner, M.B. et al. (2005) Manifestations of inflammatory arthritis are critically dependent on LFA-1. J Immunol 174: 3668-3675.
97. Watts, K.L., Cottrell, E., Hoban, P.R. and Spiteri, M.A. ( 2006) RhoA signaling modulates cyclin D 1 expression in human lung fibroblasts: Implication for idiopathic pulmonary fibrosis. Respir Res 7: 88-102.
98. Watts, K.L. and Spiteri, M. ( 2004) Connective tissue growth factor expression and induction by transforming growth factor is abrogated by simvastatin via Rho signaling mechanism. Am J Physiol Lung Cell Mol Physiol 287: L1323-L1332.
99. Weitz-Schmidt, G., Welzenbach, K., Brinkmann, V., Kamata, T., Kallen, J., Bruns, C. et al. (2001) Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 7: 687-692.
100. Yokota, K., Miyazaki, T., Hirano, M., Akiyama, Y. and Mimura, T. ( 2006) Simvastatin inhibits production of interleukin 6 (IL-6) and IL-8 and cell proliferation induced by tumor necrosing factor-α in fibroblast-like synoviocytes from patients with rheumatoid arthritis. J Rheumatol 33: 463-471.
101. Yokota, K., Miyoshi, F., Miyazaki, T., Sato, K., Yoshida, Y. and Asanuma, Y. ( 2008) High concentration simvastatin induces apoptosis in fibroblast-like synoviocytes from patients with rheumatoid arthritis. J Rheumatol 35: 193-200.
102. Youssef, S., Stüve, O., Patarroyo, J.C., Ruiz, P.J., Radosevich, J.L., Hur, E.M. et al. (2002) The HMGCoA reductase inhibitor, atorvastatin, promotes a Th 2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 420: 78-84.
103. Zhang, F.L. and Casey, P.J. ( 1996) Protein prenylation: Molecular mechanism and functional consequences. Annu Rev Biochem 65: 241-269.